A same-week expert second opinion for every rare cancer diagnosis
Rare cancers are often misdiagnosed, which sends patients down the wrong treatment path. Digital slide sharing could get every case to an expert within days.
Reference pathology review changes the diagnosis in a substantial minority of sarcoma and rare tumour cases, and diagnosis determines treatment entirely. European reference networks and national sarcoma review panels show the model works, but coverage is incomplete and turnaround is slow. Whole-slide imaging plus a funded expert rota plus AI pre-screening for likely rare entities would make it universal.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Not enough oncologists, nurses, pathologists, physicists · The number of people with cancer is rising faster than the workforce trained to treat them.
Pages like this
not linked directly; found by shared links- TrialISG-STS 1001
Shares Histotype-tailored therapy, Alessandro Gronchi, Sarcomas (soft tissue, bone, GIST).
- IdeaThe pathology lab triggers a trial referral the day a rare cancer is diagnosed
Shares Histopathology & immunohistochemistry, Digital pathology & AI, Neuroendocrine tumours, Rare and paediatric cancers without markets.
- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Fragmented care and guideline gaps, Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- InstitutionFondazione IRCCS Istituto Nazionale dei Tumori
Shares Marco Guzzo, Alessandro Gronchi, Sarcomas (soft tissue, bone, GIST).
- IdeaDigitise the nation's pathology slides and link them to outcomes
Shares Pathology & radiology foundation models, Histopathology & immunohistochemistry, Digital pathology & AI.
- IdeaRandomise inside the registry that already follows every patient
Shares Thyroid cancer, Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- ProductTrabectedin
Shares Histotype-tailored therapy, Sarcomas (soft tissue, bone, GIST).
- IdeaA funded expert second opinion for every new high-stakes or rare cancer diagnosis
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).